The company has received final approval from the United States Food
and Drug Administration (USFDA) to manufacture its generic Guaifenesin
extended-release tablets in the strengths of 600 mg and 1,200 mg.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-pharma-gets-usfda-nod-for-its-expectorant-tablets/articleshow/71740775.cms
Thursday, October 24, 2019
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment